J Tradit Chin Med. 2025 Dec;45(6):1353-1365. doi: 10.19852/j.cnki.jtcm.2025.06.014.
ABSTRACT
OBJECTIVE: To explore the clinical efficacy and potential mechanisms of Huoxue Jiedu prescription in the treatment of polycythemia vera and provide objective basis for the treatment of polycythemia vera by using network pharmacology, molecular docking technology, and clinical trials.
METHODS: First, network pharmacology and molecular docking analysis methods were used to screen the main targets of Huoxue Jiedu prescription in the treatment of polycythemia vera. Patients who were first diagnosed with polycythemia vera in the Hematology Department of Langfang Hospital of Traditional Chinese Medicine from September 2022 to January 2024 were enrolled, and a clinical randomized controlled study was conducted. Sixty patients with primary polycythemia who met the inclusion criteria were randomly divided into the treatment group and the control group, with 30 cases in each group. The control group received oral Western Medicine treatment, whereas the treatment group received oral Western Medicine combined with Huoxue Jiedu prescription treatment, and three courses were observed. The differences in the efficacy of Traditional Chinese and Western Medicine, hematological indicators, coagulation function, and expression of related targets before and after treatment were observed between the two groups. SPSS 26.0 statistical software was used for data analysis, and the treatment results of the two groups were compared to observe their clinical efficacy and mechanisms.
RESULTS: Network pharmacology results identified the phosphatidyqinositol-3 kinase (PI3K-Akt) pathway as an important pathway of Huoxue Jiedu prescription in the treatment of polycythemia veraPV, which was closely related to thrombosis. Clinical trial results showed that Huoxue Jiedu prescription improved efficacy and hematological indicators, reduced patients’ coagulation indicators such as D-dimer and fibrinogen, reduced activated partial thromboplastin time and prothrombin time, and decreased the expression of PI3K and Serine/threonine-protein kinase AKT1 (AKT1) mRNA in peripheral blood.
CONCLUSION: Network pharmacology predicted the corresponding targets of traditional Chinese medicine to a certain extent. Huoxue Jiedu prescription could enhance clinical efficacy, improve hematological indicators, and reduce coagulation indicators through antithrombotic effect by inhibiting the expression of PI3K and AKT1.
PMID:41376227 | DOI:10.19852/j.cnki.jtcm.2025.06.014
